#ViiV Healthcare

ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.

Virtually, of course. So take a look around.

4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.

The single-tablet regimen is now approved for previously treated people with an undetectable viral load.

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

Nine findings from ViiV Healthcare’s Latinx Listening Initiative

Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.

A global study examined how outcomes improve when physicians engage their HIV-positive patients in joint decision-making.

The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.

Plus: Their stigma-busting initiative gets a shout-out from POZ’s Best Celebrity Advocate 2019.

The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.

A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.

Bonus: Your donations to the Broadway Cares effort Emergency Grants for Pandemic Relief will be matched by Gilead Sciences.